- Gilead Sciences Inc. and EVOQ Therapeutics Inc. are partnering to develop autoimmune disorder treatments in a deal worth up to $658.5 million. The companies will collaborate on preclinical work for rheumatoid arthritis and lupus treatments, and Gilead will then conduct clinical development and the commercialization of candidates. (Article here)
January 4, 2023
Life Sciences